GLSI - Greenwich LifeSciences enters into $100M open market sale agreement
- Greenwich LifeSciences ( NASDAQ: GLSI ) entered into an Open Market Sale Agreement with Jefferies as sales agent wherein it may issue and sell from time to time shares par value $0.001/ share.
- It may issue and sell stock having total offering price of up to $100M.
- Net proceeds to be used for general corporate purposes, which may include, among other things, funding the clinical development and manufacturing and expenses for GP2, research and development, general and administrative expenses, license or technology acquisitions, and working capital expenditures.
- Separately, the company rallied in early trading today after U.S. FDA removed a clinical hold on a phase 3 trial in breast cancer allowing it to progress.
For further details see:
Greenwich LifeSciences enters into $100M open market sale agreement